Literature DB >> 20335424

Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.

M A Pfaller1, M Castanheira, D J Diekema, S A Messer, G J Moet, R N Jones.   

Abstract

The antifungal broth microdilution (BMD) method of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and the Etest agar diffusion method were compared with the Clinical and Laboratory Standards Institute (CLSI) BMD method M27-A3 for anidulafungin, caspofungin, and micafungin susceptibility testing of 133 clinical isolates of Candida species. The isolates were characterized for the presence or absence of fks1 and/or fks2 gene mutations and included 34 isolates of C. glabrata (4 mutant strains), 32 of C. albicans (1 mutant strain), 25 of C. parapsilosis, 19 of C. guilliermondii, 12 of C. tropicalis (2 mutant strains), and 11 of C. krusei. Excellent essential agreement (EA; within 2 dilutions) between the CLSI and EUCAST and CLSI and Etest MIC results was observed. The overall EA between the EUCAST and CLSI results ranged from 89.5% (caspofungin) to 99.2% (micafungin), whereas the EA between the Etest and CLSI results ranged from 90.2% (caspofungin) to 93.2% (anidulafungin). The categorical agreement (CA) between methods for each antifungal agent was assessed using previously determined epidemiological cutoff values (ECVs). Excellent CA (>90%) was observed for all comparisons between the EUCAST and CLSI results with the exceptions of C. glabrata and caspofungin (85.3%) and C. krusei and caspofungin (54.5%). The CA between the Etest and CLSI results was also excellent for all comparisons, with the exception of C. krusei and caspofungin (81.8%). All three methods were able to differentiate wild-type (WT) strains from those with fks mutations. With anidulafungin as the test reagent, the CLSI method identified 5 of 7 mutant strains, whereas the EUCAST method and the Etest identified 6 of 7 mutant strains. With either caspofungin or micafungin as the test reagent, the CLSI method identified all 7 mutant strains and the EUCAST method identified 6 of 7 mutant strains. The Etest identified all 7 mutant strains using caspofungin as the reagent. All three test methods showed a high level of agreement and of ability to distinguish fks mutant strains of Candida species from WT strains using each of the echinocandins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20335424      PMCID: PMC2863935          DOI: 10.1128/JCM.02445-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  38 in total

1.  Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species.

Authors:  Manuel Cuenca-Estrella; Wendy Lee-Yang; Meral A Ciblak; Beth A Arthington-Skaggs; Emilia Mellado; David W Warnock; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria.

Authors:  Gunnar Kahlmeter; Derek F J Brown; Fred W Goldstein; Alasdair P MacGowan; Johan W Mouton; Anders Osterlund; Arne Rodloff; Martin Steinbakk; Pavla Urbaskova; Alkiviadis Vatopoulos
Journal:  J Antimicrob Chemother       Date:  2003-07-01       Impact factor: 5.790

3.  [Study of in vitro activity of caspofungin on non-Candida albicans yeast strains determined by two methods: M27-A2 and EUCAST].

Authors:  M Romero; E Cantón; J Pemán; M Gobernado
Journal:  Rev Esp Quimioter       Date:  2004-09       Impact factor: 1.553

4.  Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.

Authors:  Santosh Katiyar; Michael Pfaller; Thomas Edlind
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

5.  Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.

Authors:  J Turnidge; G Kahlmeter; G Kronvall
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067

6.  Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species.

Authors:  M A Pfaller; S A Messer; K Mills; A Bolmström; R N Jones
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

7.  Evaluation of the in vitro activity of caspofungin against bloodstream isolates of Candida species from cancer patients: comparison of Etest and NCCLS reference methods.

Authors:  M Laverdiere; C Restieri; F Habel
Journal:  Int J Antimicrob Agents       Date:  2002-12       Impact factor: 5.283

8.  Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories.

Authors:  E Dannaoui; A Paugam; M Develoux; C Chochillon; J Matheron; A Datry; C Bouges-Michel; C Bonnal; F Dromer; S Bretagne
Journal:  Clin Microbiol Infect       Date:  2009-09-23       Impact factor: 8.067

9.  Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions.

Authors:  Shiang Ning Leaw; Hsien Chang Chang; Hsiao Fang Sun; Richard Barton; Jean-Philippe Bouchara; Tsung Chain Chang
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

10.  Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.

Authors:  Michel Laverdière; Richard G Lalonde; Jean-Guy Baril; Donald C Sheppard; Steven Park; David S Perlin
Journal:  J Antimicrob Chemother       Date:  2006-02-07       Impact factor: 5.790

View more
  41 in total

Review 1.  Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

2.  In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?

Authors:  Susanne Perkhofer; Cornelia Mrazek; Lukas Hartl; Cornelia Lass-Flörl
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

3.  Comparative evaluation of a new commercial colorimetric microdilution assay (SensiQuattro Candida EU) with MIC test strip and EUCAST broth microdilution methods for susceptibility testing of invasive Candida isolates.

Authors:  Hedda Luise Koehling; Birgit Willinger; Jan Buer; Peter-Michael Rath; Joerg Steinmann
Journal:  J Clin Microbiol       Date:  2014-11-12       Impact factor: 5.948

Review 4.  Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.

Authors:  David S Perlin
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

Review 5.  Antifungal drug discovery: the process and outcomes.

Authors:  Richard Calderone; Nuo Sun; Francoise Gay-Andrieu; William Groutas; Pathum Weerawarna; Sridhar Prasad; Deepu Alex; Dongmei Li
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165

6.  Intra- and Interlaboratory Agreement in Assessing the In Vitro Activity of Micafungin against Common and Rare Candida Species with the EUCAST, CLSI, and Etest Methods.

Authors:  J Meletiadis; E Geertsen; I Curfs-Breuker; J F Meis; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

7.  Recurrent episodes of candidemia due to Candida glabrata with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin.

Authors:  María Teresa Durán-Valle; Sara Gago; Alicia Gómez-López; Manuel Cuenca-Estrella; Leticia Jiménez Díez-Canseco; José Luis Gómez-Garcés; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

Review 8.  Antifungal Susceptibility Testing: Current Approaches.

Authors:  Elizabeth L Berkow; Shawn R Lockhart; Luis Ostrosky-Zeichner
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

9.  Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

Authors:  Barbara D Alexander; Melissa D Johnson; Christopher D Pfeiffer; Cristina Jiménez-Ortigosa; Jelena Catania; Rachel Booker; Mariana Castanheira; Shawn A Messer; David S Perlin; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

10.  Evaluation of the "Dip Effect" Phenomenon in Antifungal Susceptibility Testing of Candida spp. against Echinocandins by Use of Gradient Concentration Strips.

Authors:  Maria Siopi; Marilena Tsala; Nikolaos Siafakas; Loukia Zerva; Joseph Meletiadis
Journal:  J Clin Microbiol       Date:  2015-09-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.